Join
Live feed
·
PRReleasevia Quantisnow
Opus Genetics Inc. logo

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

ByQuantisnow·Wall Street's wire, on your screen.
IRD· Opus Genetics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IRD (Opus Genetics Inc.) and more on Quantisnow.